▲ Peaking
Business
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte's stock jumps 27% as pneumococcal vaccine holds its own against Pfizer's and Merck's shots.
Pfizer
8 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Pfizer
This hub groups 8 separate news trends connected to Pfizer, spanning June 23, 2026 through October 5, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 74 article observations and 72 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
🔮 fades ✓
What you need to know about this year’s fall vaccines
25 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon
The FDA has approved new Covid vaccines, but the companies that make them are already talking about availability.
◼ Archived
Business
🔮 fades ✓
What to Know About New Covid Vaccines for Fall 2026
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping.
Pfizer's Covid pill revenue has dropped 95%, driving a shift in the company's financial strategy.
◼ Archived
Business
🔮 fades ✓
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
NIKE, Inc. Announces Planned CFO Transition —
Nike has appointed former Pfizer executive David Denton as its new CFO during a period of strategic turnaround.
◼ Archived
Business
🔮 fades ✓
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.